Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 14/20 | 0.73 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.73 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.73 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.73 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.73 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalamide SCHEMBL3444098 | 0.88 | LOXL2 (0.60) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL509167 | 0.88 | LOXL2 (0.60) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31474725 | 0.86 | LOXL2 (0.58) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3948480 | 0.86 | LOXL2 (0.58) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL3137816 | 0.85 | PARP10 (1.00) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL26116709 | 0.85 | SRD5A2 (0.66) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL12238994 | 0.84 | PARP10 (0.76) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL21628385 | 0.83 | PARP10 (0.70) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL3789265 | 0.83 | ST14 (0.83) | PARP10PARP15PARP14PARP4ALDH1A1 | |
| SCHEMBL4209153 | 0.81 | ST14 (0.85) | ST14LOXL2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | PARP10 1540/4885PARP15 1732/4885PARP14 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.